Sanwa Kagaku Kenkyusho Co., Ltd.

Hiroshi Ozawa

Masayasu Kurono

Kiichi Sawai

Ryoichi Unno

Yasuaki Kondo

Kenji Miura

Toshinao Usui

Kyoichi Asano

Takuji Yamaguchi

Masato Fukushima

Noriaki Kato

Akira Matsubara

Kuniharu Mizuno

Naofumi Terada

Takahiko Mitani

Takahito Jomori

Yukiharu Matsumoto

Hiromoto Kimura

Tsunemasa Suzuki

Tomoo Suzuki

Kiyotaka Hirooka

Hisashi Michishita

Masahiko Koketsu

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group,

Hydantoin derivatives for treating complications of diabetes

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group,

Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivative, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitogen or oxygen atom, ##STR3## in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group,

1-Pyrrolidineacetamide derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen atom or a trialkylsilyl group, R.sub.2 and R.sub.3 are hydrogen atom, respectively, when R.sub.1 is hydrogen atom, R.sub.4 is an alkyl group, R.sub.5 is a radical of ##STR2## in which R.sub.6 and R.sub.7 are an alkyl group, respectively, m and n are an integer of 1 to 3, respectively,

1-pyrrolidineacetamide derivatives and use thereof

An organo-silicone compound of the formula ##STR1## wherein X is a methylene or carbonyl radical, Y is an NH or O, n is an integer, R.sub.1 is a hydrogen atom, halogen atom or alkyl group, R.sub.2, R.sub.3 and R.sub.4 are an alkyl group, alkoxy group, phenyl radical or substituted phenyl radical, respectively, and R.sub.5 is a hydrogen atom or a group of ##STR2## in which X, Y, n, R.sub.2, R.sub.3 and R.sub.4 have the meanings as referred to, and used as an anti-tumor agent or for use in anti-tumor compositions.

Uracil derivatives for use as anti-tumor agents having silicon

Growing community of inventors

Nagoya, Japan

Hiroshi Ozawa